PharmacyCodes



Quinidex Extentabs en es it fr

Categorie

Quinidex Extentabs Les marques, Quinidex Extentabs Analogs

Quinidex Extentabs Les marques melange

  • No information avaliable

    • Quinidex Extentabs Formule chimique

    C20H24N2O2

    Quinidex Extentabs RX lien

    http://www.rxlist.com/cgi/generic/quinidine.htm

    Quinidex Extentabs FDA fiche

    Quinidex_Extentabs FDA

    Quinidex Extentabs msds (fiche de securite des materiaux)

    Quinidex Extentabs Synthese de reference

    Aucune information disponible

    Quinidex Extentabs Poids moleculaire

    324.417 g/mol

    Quinidex Extentabs Point de fusion

    174 oC

    Quinidex Extentabs H2O Solubilite

    140 mg / L

    Quinidex Extentabs Etat

    Solid

    Quinidex Extentabs LogP

    2.534

    Quinidex Extentabs Formes pharmaceutiques

    Solution

    Quinidex Extentabs Indication

    Pour le traitement de pré-excitation ventriculaire et des arythmies cardiaques

    Quinidex Extentabs Pharmacologie

    Quinidine, un anticonvulsivant hydantoïne, est utilisé seul ou avec des anticonvulsivants phénobarbital ou d'autres pour gérer les crises tonico-cloniques, convulsions psychomotrices, syndromes de douleur neuropathique diabétique, y compris les neuropathie, induites par les digitaliques arythmies cardiaques, et les arythmies cardiaques associées à intervalle QT prolongation.

    Quinidex Extentabs Absorption

    Aucune information disponible

    Quinidex Extentabs Toxicite

    Aucune information disponible

    Quinidex Extentabs Information pour les patients

    Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected. Discussion should include the facts

    • that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
    • that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
    • that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
    • that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

    To confirm whether this is the most current prescribing information available on Quinaglute®, or to obtain the most current prescribing information, please call Berlex Laboratories at 1-888-BERLEX-4 (choose option #4, Product Usage Information).

    Quinidex Extentabs Organismes affectes

    Les humains et autres mammifères